A step-by-step profile-building case study through AdvanceMyProfile.com
He worked for a company. His patents were assigned to his employer. His publications were limited by
business and IP strategy. His salary was exceptional. Most importantly, he had helped create therapeutic
biologics that were moving toward human clinical testing. Industry scientists often assume EB-1A belongs only
to professors with large publication records. This case shows why that assumption is wrong.
| Nationality | Chinese |
| Working in | United States (H-1B, principal scientist at mid size biotech company) |
| Profession | R&D scientist, protein engineering and therapeutic biologics discovery |
| Career stage | Approx. 11 years post-PhD; principal scientist level |
| Pathway | EB-1A Extraordinary Ability |
| Prior petition | None |
| When he came to us | Active H-1B; no prior I-140; assumed EB-1A required an academic record |
| Engagement with us | Approx. 11 months |
| Outcome | EB-1A approved; adjustment strategy prepared using Singapore spouse chargeability (representative) |
The scientist and the assumption that almost stopped him:
He had spent eleven years in laboratories where the work was valuable because it was difficult to show too early. As a principal scientist at a mid-size biotechnology company, he worked on protein engineering and therapeutic biologics discovery. His role involved solving binding, stability, and molecular-design problems that can determine whether a biologic remains a promising concept or moves toward a regulated development pathway.
His strongest contributions were visible in a form that many industry scientists undervalue for immigration purposes: patents, regulatory progress, senior compensation, and program leadership. He was named on multiple granted patents. His limited publications had still received independent citations. One program he helped lead had moved to the Investigational New Drug stage, a major point in the life of a therapeutic candidate.
Yet he nearly did not file. He believed EB-1A belonged to academics with long publication lists, large laboratories, and dozens of PhD students. He also believed that because the patents were assigned to his employer, they did not count as his evidence. Both assumptions were wrong. The case did not require him to become an academic. It required us to document the extraordinary record he had already built inside industry.
Chinese nationals: chargeability and the options:
For mainland China-born applicants, the EB-2 backlog can be long. The EB-1A queue is usually shorter, which makes EB-1A an important strategy when the evidence genuinely supports the higher extraordinary-ability standard. This does not eliminate the need for careful timing, but it can materially improve the long-term path compared with remaining only in EB-2.
He had no prior approved I-140, so priority-date retention was not available. His spouse, however, was born in Singapore, a country with no significant EB-1A backlog. Filing together using spouse cross chargeability could make the priority date current if the EB-1A was approved. This chargeability analysis was not an afterthought. It shaped the value of the entire strategy from the beginning.
The patent question: assigned to the employer does not erase the inventor:
In biotechnology, employee inventions are commonly assigned to the company. The company owns the patent rights, manages licensing, and controls commercial strategy. That is normal. It does not erase the inventor’s role.
A granted patent still lists the individual inventors on the face of the document. That listing is an official, public, permanent record that the named person contributed to the invention. For EB-1A, the question is not who owns the patent as an asset. The question is whether the petitioner made an original contribution and whether that contribution has significance in the field.
He had five granted USPTO patents, including three where his role was central to the claimed invention. We placed those patents at the front of the original contribution evidence. We also explained their relationship to the company’s biologics pipeline so the officer could see that the patents were not isolated filings. They were part of a real therapeutic development record.
The EB-1A criteria map: what an industry biotech scientist can show:
The case did not depend on converting an industry scientist into a university researcher. We mapped his real evidence against the EB-1A criteria and built the petition around the strongest available proof.
| EB-1A Criterion | Evidence / Assessment |
| High salary or remuneration | Principal scientist compensation documented through W-2 records, employment agreement, and biotech-specific compensation surveys. His total remuneration placed him at or above the upper tier for biomedical scientists at comparable seniority. |
| Original contributions of major significance | Five granted USPTO patents, including three with a central inventor role, supported by citations to his peer-reviewed papers and evidence that the patented work related to a therapeutic biologics program moving through regulated development. |
| Leading or critical role for a distinguished organization | Principal scientist and technical lead on a therapeutic biologics program that reached the IND stage, with company documentation showing that his work was central to the program’s scientific basis. |
| Judging the work of others | Peer review for biomedical and pharmaceutical science journals, plus invited service on an R&D-focused scientific advisory panel for a biotechnology industry association. |
| Scholarly articles | Limited but legitimate peer-reviewed publications in protein engineering and therapeutic biologics, with independent citations from academic and industry researchers. |
| Published material about the petitioner or his work | Industry coverage of the company’s biologics program, references to the IND milestone, and professional commentary on protein-engineering advances. |
| Membership | Standard professional memberships existed, but no selective fellowship was relied upon because it was not the strongest or most natural evidence for this profile. |
The IND milestone: translating biotech language into immigration evidence:
The Investigational New Drug stage was one of the most important facts in the case. Outside biotechnology, many readers do not immediately understand what it means. We therefore explained it directly.
An IND filing is the point at which a sponsor submits enough preclinical, manufacturing, and safety information for the FDA to allow a therapeutic candidate to move toward human clinical testing. It does not mean approval of the medicine. It does mean the scientific and regulatory record has reached a formal threshold where a federal regulator is now involved in the development pathway.
He was the principal scientist connected to the molecular mechanism and preclinical development that supported this program. We documented that role through company letters, program records, and a carefully written explanation of the IND process. The goal was not to over claim. The goal was to help a USCIS officer understand why this was stronger evidence than an ordinary internal project.
Working within industry constraints instead of pretending they do not exist:
Industry scientists often cannot publish everything they know. In biotechnology, early disclosure can compromise patents, competitive position, and regulatory strategy. That reality does not weaken the profile when it is explained honestly and supported by other evidence.
We treated his publications as supporting evidence, not the center of the case. The patents, the IND-stage program, the salary record, the judging activity, and independent letters carried the main weight. Where publications existed, we documented the journals, the citations, and the independence of the citing researchers. Where publications did not exist, we explained why patents and regulatory milestones were the more natural evidence for an industry scientist.
We also prepared a field-facing technical white paper on protein-engineering pathways for therapeutic biologics. It did not disclose protected company IP. It was shared with appropriate biotechnology research and industry audiences, including a biotech professional association committee, a therapeutic biologics research network, and selected industry stakeholders. Its purpose was evidence-building with credibility: to show thought leadership in the field without compromising proprietary information.
Independent letters and the full evidence architecture:
The recommendation strategy had to be independent. We sourced letters from a protein-engineering academic whose lab had cited his mechanism-related publications, a journal editor who could verify the significance of his peer-review work, a senior biotech scientist outside his company who could explain his standing in the therapeutic biologics field, and an industry analyst familiar with the clinical-development significance of an IND stage program.
The strongest letters did not merely say he was talented. They explained why his specific work mattered: how his protein-engineering methods contributed to therapeutic design, why his patents reflected meaningful invention, and why the IND-stage program showed that his work had moved beyond laboratory speculation into a regulated development pathway.
We then assembled the petition so the evidence moved in a logical sequence: patents and invention, regulatory progress, salary and market recognition, peer review and judging, publications and citations, independent letters, and chargeability strategy. The final case did not read like a professor’s file. It read like what it was: an industry scientist’s extraordinary-ability record.
The approval and what changed after it:
The EB-1A petition was approved without a request for evidence. With Singapore chargeability available through his spouse, the adjustment strategy could move forward without the long China born queue controlling the next step. Employment authorization and travel planning were handled through the adjustment process in the usual manner.
Professionally, the profile-building work also changed how he was seen inside and outside his company. The same evidence used for immigration gave him a clearer public record of his role in the company’s therapeutic platform. After the approval, he was appointed to a broader scientific leadership role connected to biologics pipeline strategy and received compensation adjustments consistent with that expanded responsibility.
He told us that the most important shift was understanding that employer-assigned patents were not invisible. They were company assets, yes, but they were also public records of his inventive contribution. Once that became clear, the rest of the case could be built around evidence he already had but had not known how to use.
What this case teaches:
- Employer assigned patents can still be personal EB-1A evidence. The company may own the rights, but the USPTO still lists the inventors. That official listing is powerful evidence of original contribution.
- IND stage progress can support critical-role evidence when explained correctly. It is not a drug approval and should not be described as one. It is a formal regulatory milestone showing that the scientific work has advanced to a level requiring FDA review.
- Industry scientists do not need to look like professors. Limited publications may be normal where IP strategy controls disclosure. Patents, regulatory milestones, salary, leadership, and independent expert letters may be more natural evidence.
- Biotech salary evidence must use biotech-specific comparables. General STEM salary data is weaker. Field and seniority specific compensation surveys make the high salary criterion more credible.
- White papers must protect proprietary information. Where used, they should be shared with credible biotechnology, research, or industry audiences and should support field recognition without exposing protected company IP.
- Chinese nationals should check spouse cross-chargeability early. A spouse born in a current chargeability country, such as Singapore in this case, can materially change the adjustment strategy when both spouses file and immigrate together.
If you are an industry scientist with patents, regulatory milestones, and limited publications because of company strategy, your record may be stronger than it appears. A free, honest assessment can show which EB-1A criteria your actual career may already satisfy.